1. Role of Conversion Surgery for Unresectable Pancreatic Cancer After Long‐Term Chemotherapy
   Nobuhiro Tsuchiya et al, 2020, World Journal of Surgery CrossRef
2. Clinical Benefits of Conversion Surgery for Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Institution, Retrospective Analysis
   Yuko Mataki et al, 2021, Cancers CrossRef
3. Enhanced mitochondrial co-localization of β-escin micelle and pancreatic tumor accumulation relation
   Burcu Uner et al, 2023, Journal of Drug Delivery Science and Technology CrossRef
4. Novel Paclitaxel Nanoformulation Impairs De Novo Lipid Synthesis in Pancreatic Cancer Cells and Enhances Gemcitabine Efficacy
   Advait Shetty et al, 2020, ACS Omega CrossRef
5. Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma
   Hiroaki Yanagimoto et al, 2020, Cancers CrossRef
6. Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer “in a Korean” population: A single-center cohort study
   In Rae Cho et al, 2017, Seminars in Oncology CrossRef
7. Successful treatment of a locally advanced unresectable pancreatic cancer patient with interstitial pneumonitis by conversion surgery following gemcitabine plus nab‑paclitaxel chemotherapy: A case report
   Tetsuo Yokota et al, 2019, Molecular and Clinical Oncology CrossRef
8. Thermosensitive and biodegradable hydrogel encapsulating targeted nanoparticles for the sustained co-delivery of gemcitabine and paclitaxel to pancreatic cancer cells
   Ahmed M. Shabana et al, 2021, International Journal of Pharmaceutics CrossRef
9. Conversion surgery with gemcitabine plus nab‑paclitaxel for locally advanced unresectable pancreatic cancer: A case report
   Ryosuke Okura et al, 2018, Molecular and Clinical Oncology CrossRef
10. Currently available first-line drug therapies for treating pancreatic cancer
    Jennifer L. Olson et al, 2018, Expert Opinion on Pharmacotherapy CrossRef
11. Interstitial lung disease in advanced pancreatic ductal adenocarcinoma patients treated with gemcitabine and nab-paclitaxel combination therapy: a retrospective analysis
    Hiroki Irie et al, 2020, Cancer Chemotherapy and Pharmacology CrossRef
12. Advances of pathological complete response after neoadjuvant therapy for pancreatic cancer
    Lingdi Yin et al, 2019, Journal of Pancreatology CrossRef
13. Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study
    Heng‐Chung Kung et al, 2023, MedComm CrossRef
14. Survival benefit of conversion surgery for patients with initially unresectable pancreatic cancer who responded favorably to nonsurgical treatment
    Toshimichi Asano et al, 2018, Journal of Hepato-Biliary-Pancreatic Sciences CrossRef
15. Context Matters—Why We Need to Change From a One Size Fits all Approach to Made-to-Measure Therapies for Individual Patients With Pancreatic Cancer
    Sushmitha Sankarasubramanian et al, 2021, Frontiers in Cell and Developmental Biology CrossRef
16. A successful case of locally advanced pancreatic cancer undergoing curative distal pancreatectomy with en bloc celiac axis resection after combination chemotherapy of nab-paclitaxel with gemcitabine
    Masahide Hiyoshi et al, 2017, Clinical Journal of Gastroenterology CrossRef
17. Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review
    Fabiana Napolitano et al, 2019, Cancers CrossRef
18. The treatment and survival of elderly patients with locally advanced pancreatic cancer: A post-hoc analysis of a multicenter registry
    L.J.H. Brada et al, 2021, Pancreatology CrossRef
19. Myeloid-Derived Suppressor Cells and Pancreatic Cancer: Implications in Novel Therapeutic Approaches
    Anita Thyagarajan et al, 2019, Cancers CrossRef
20. A Review on the Efficacy and Safety of Nab-Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer
    Christian Chapa-González et al, 2022, Life CrossRef
21. Current trends and issues of conversion surgery for patients with locally advanced unresectable pancreatic cancer
    Toshimichi ASANO et al, 2018, Suizo CrossRef